Edited animals are in the news this week. Wired dedicates its cover story to “A more human livestock industry, brought to you by CRISPR,” focusing on experiments being done at the University of California, Davis. Alison Van Eenennaam is trying to alter sexual traits in cattle by targeting a single gene called SRY. The science is still difficult, however, and US regulations uncertain. Continue reading
Where is Jennifer Doudna? This is the first thought most journalists had – me included – when reading the list of signatories to the call for the moratorium on heritable genome editing just published by Nature. The Boston team is well represented by Lander, Zhang and Liu (nobody would expect George Church to join that call). But the magnificent couple Doudna-Charpentier has conspicuously split up. Continue reading
Pollination is a natural way to deliver DNA into plant cells. So why not to use pollen as a vehicle for CRISPR machinery to start genome editing? HI Edit, as this approach is called, has been successfully tested by Syngenta in corn, Arabidopsis and wheat in the lab. Please see the paper just published in Nature Biotechnology by Timothy Kelliher et al., Jon Cohen’s piece in Science, and a quick guide to HI (haploid induction) from Current Biology. Leading wheat geneticist Cristobal Uauy of the John Innes Centre also showed high spirit, when asked for comment by email: “The possibility to genome edit any variety is revolutionary given that transformation is so difficult in many species. If I understand this correctly this would be a game changer as it would allow us to alter genes in elite cultivars.”
Yesterday was the Rare Disease Day, and I was awarded the special prize OMaR-Eugenio Aringhieri for my CRISPR blog and book, thank you!
In 2013, multiple labs sharpened CRISPR molecular scissors against Duchenne muscular dystrophy, using cells from patients in vitro. In 2016, the dystrophin gene was successfully edited in mice. Then last summer, Eric Olson did it in dogs . Where are we now in the struggle to cure this severe type of myopathy afflicting 300,000 boys in the world? What is still needed to move into a clinical trial? Continue reading